Elevance Health, Inc. $ELV Shares Sold by Legal & General Group Plc

Legal & General Group Plc lowered its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 2.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,866,369 shares of the company’s stock after selling 54,984 shares during the period. Legal & General Group Plc’s holdings in Elevance Health were worth $654,256,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. New Age Alpha Advisors LLC boosted its stake in Elevance Health by 7.2% during the 4th quarter. New Age Alpha Advisors LLC now owns 8,752 shares of the company’s stock worth $3,068,000 after purchasing an additional 590 shares during the period. HBK Sorce Advisory LLC boosted its stake in Elevance Health by 6.9% during the 4th quarter. HBK Sorce Advisory LLC now owns 794 shares of the company’s stock worth $269,000 after purchasing an additional 51 shares during the period. Hantz Financial Services Inc. boosted its stake in Elevance Health by 48.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,064 shares of the company’s stock worth $373,000 after purchasing an additional 347 shares during the period. Allen Capital Group LLC boosted its stake in Elevance Health by 4.0% during the 4th quarter. Allen Capital Group LLC now owns 13,784 shares of the company’s stock worth $4,832,000 after purchasing an additional 524 shares during the period. Finally, Wealthquest Corp acquired a new stake in Elevance Health during the 4th quarter worth $377,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Down 0.1%

ELV stock opened at $394.41 on Tuesday. The company has a fifty day moving average of $335.93 and a 200-day moving average of $336.96. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a market capitalization of $85.65 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 2.23 and a beta of 0.66. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $408.00.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts expect that Elevance Health, Inc. will post 26.91 EPS for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays raised their target price on shares of Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. Evercore restated a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Finally, Jefferies Financial Group reduced their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and an average price target of $399.32.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.